Clinical Trial Update: Efficacy, Safety and Tolerability of Everolimus in Preventing End-stage Renal Disease in Patients With Autosomal Dominant Polycystic Kidney Disease [Phase 4]

View source ↗

Summary

This clinical trial update reports on the efficacy, safety and tolerability of everolimus in preventing end-stage renal disease in autosomal dominant polycystic…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Autosomal Dominant Polycystic Kidney Disease

Drugs mentioned

• Afinitor (everolimus)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Autosomal Dominant Polycystic Kidney Disease | Phase 4 | Status: COMPLETED | Results posted: 2015-01-14